Purpose Women with breast cancer frequently use antidepressants; however, questions about the effect of these medications on breast cancer recurrence remain. Methods We identified 4,216 women C18 years with an incident stage I or II breast cancer diagnosed between 1990 and 2008 in a mixed-model healthcare delivery system linked to a cancer registry. Recurrences were ascertained from chart review. Medication exposures were extracted from electronic pharmacy records. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95 % confidence intervals (CI) to assess the association between antidepressant use and breast cancer recurrence and mortality. We also conducted analyses restricted to tamoxifen users. Results Antidepressants overall, tricyclic antidepressants, and selective serotonin reuptake inhibitors were not associated with risk of breast cancer recurrence or mortality. Women taking paroxetine only (adjusted HR: 1.66; 95 % CI 1.02, 2.71) and trazodone only (adjusted HR: 1.76; 95 % CI 1.06, 2.92), but not fluoxetine only (adjusted HR: 0.92; 95 % CI 0.55, 1.53), had higher recurrence risks than antidepressant nonusers. There was some suggestion of an increased recurrence risk with concurrent paroxetine and tamoxifen use compared with users of tamoxifen only (adjusted HR: 1.49; 95 % CI 0.79, 2.83). Conclusions In general, antidepressants did not appear increase risk of breast cancer recurrence, though there were some suggested increases in risk that warrant further investigation in other datasets. Our results combined systematically and quantitatively with results from other studies may be useful for patients and providers making decisions about antidepressant use after breast cancer diagnosis.
Introduction
Antidepressant use is common among women with breast cancer in the USA, with upward of one-quarter to one-third of women using these medications after their cancer diagnosis [1] [2] [3] . Thus, understanding the safety of antidepressants is important for the health of the growing number of breast cancer survivors.
Tamoxifen is an important treatment for hormone receptor-positive breast cancer [4] . Inhibitors of the enzyme CYP2D6, such as the selective serotonin reuptake inhibitors (SSRIs) paroxetine and fluoxetine, may impair conversion of tamoxifen into its active form, endoxifen [5] [6] [7] [8] . The clinical importance of their potential inhibitory effects is unknown and questionable, especially since studies suggest that even genetic variants of CYP2D6 Electronic supplementary material The online version of this article (doi:10.1007/s10552-015-0689-y) contains supplementary material, which is available to authorized users. encoding reduced enzymatic activity do not result in worse outcomes [9] [10] [11] [12] [13] ; however, there is much debate on the effects of these medications in women with breast cancer [14] [15] [16] [17] [18] [19] , and the Food and Drug Administration (FDA) has issued precautions regarding concomitant use of tamoxifen and paroxetine [20, 21] .
Epidemiologic research on antidepressant use and breast cancer outcomes varies considerably in exposures and outcomes studied [1, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Studies of antidepressants that weakly inhibit CYP2D6 (such as citalopram) have generally not been associated with breast cancer recurrence risk [22, 23, 31] . However, there has been some suggestion of increased risk of breast cancer recurrence [22] and breast cancer mortality [27] among patients who use tamoxifen with the strong CYP2D6 inhibitor paroxetine in some but not all studies [25] . Studies of CYP2D6 inhibitors in general (including medications other than antidepressants) [26] , antidepressants with moderate/strong CYP2D6 affinity [30] , and SSRIs in as a class [1, 28, 31] have generally not suggested an association with breast cancer outcomes among tamoxifen users. Of note, studies lacked statistical precision and little information was available on the commonly used antidepressant fluoxetine, which also inhibits CYP2D6. We therefore assessed the association between different classes of antidepressants and individual medications and the risk of breast cancer recurrence.
Methods

Study overview
This cohort study, Commonly Used Medications and Breast Cancer Outcomes (COMBO), is described in detail elsewhere [32, 33] . Briefly, we conducted this study within the western Washington region of Group Health, a mixedmodel health plan in Washington state and northern Idaho. Study participants had to reside in one of the 13 western Washington counties covered by the western Washington Surveillance, Epidemiology, and End Results program (SEER) registry. We used cancer registry files linked to Group Health enrollment files to identify women aged 18 years and older who were diagnosed with a first primary stage I or II invasive breast cancer between 1990 and 2008, inclusive. Participants had to be enrolled in Group Health's Integrated Group Practice model for the year before and after their incident breast cancer diagnosis (unless they died during that year). Medical records of potentially eligible participants (n = 4,426) were reviewed. We excluded participants with no medical record (n = 72), bilateral disease (n = 6), recurrent or second primary breast cancers that were incorrectly identified as incident first breast cancers (n = 79), and no definitive surgery (n = 44). We required women be alive and recurrence free for 120 days after surgery and therefore excluded people who died (n = 5) or had metastases (n = 4) within 120 days of surgery. The final cohort consisted of 4,216 women. Fiveyear outcomes from a subset of this cohort (n = 1,306) were included in an earlier report on antidepressants and breast cancer outcomes [1] . The Group Health human subjects review committee approved all study procedures.
The SEER registry provided data on tumor characteristics and certain patient characteristics. When these were not available in SEER, we abstracted them from medical records as part of a detailed chart abstraction [31, 32] . Charts were abstracted from 1 year before diagnosis through patient death, disenrollment from Group Health, or the date of chart abstraction. Data elements included treatment of the incident breast cancer, breast cancer recurrences and second primaries [34] . Data on comorbidity diagnoses (including mental health diagnoses [Supplemental Table 1 ] and the Charlson comorbidity score [35] ), health history and medication use, height, weight, and date and cause of death came primarily from administrative data sources and the electronic medical record at Group Health. A list of data elements and their sources was previously published by Boudreau and colleagues [32] .
Exposure
Group Health's pharmacy database provided information on prescription fills at Group Health-owned pharmacies and pharmacy claims throughout the entire study period [36, 37] . Each record contained information on the drug dispensed, including national drug code (NDC), quantity, strength, days' supply, date dispensed, and prescriber. Drug exposures of interest included use of the following after breast cancer diagnosis: (1) any antidepressant, (2) any SSRI, (3) any tricyclic antidepressant (TCA), and (4) any miscellaneous antidepressant. We further classified SSRI use into strong CYP2D6 inhibitors (paroxetine, fluoxetine, and buproprion) and weak/moderate CYP2D6 inhibitors (sertraline, citalopram, fluvoxamine, and escitalopram) [2, 30] .
For each drug and drug class, we defined episodes of use. We used the days' supply field to compute the intended duration of each prescription [1, 32] . Assuming 80 % adherence, we calculated prescriptions' run-out date by multiplying days' supply by 1.25 [38] . If a new prescription for the drug or class of interest was dispensed \60 days after the run-out date of the preceding prescription, it was included as part of the same episode of use. Episodes started on the dispensing day of the first prescription and ended on the run-out day of the last prescription [32] . Once someone became a user after breast cancer diagnosis, she remained a user, regardless of when she discontinued use. The rationale for this was that any post-diagnosis use-not necessarily current use-could be related to recurrence risk. Concurrent use between antidepressants and endocrine therapy (tamoxifen or aromatase inhibitors) was defined as an overlap of C60 days of use [28] . In a sensitivity analysis, we required C180 days.
Information on endocrine therapy (tamoxifen and aromatase inhibitors) was obtained from prescription fills. Like all other exposure variables, concurrent antidepressant use was time varying and unidirectional. Once someone became a concurrent user, she remained a concurrent user, even if she discontinued use of either the antidepressant or tamoxifen. A non-concurrent user could become a concurrent user if the 60 days of overlap was achieved (Supplemental Figure 1 ).
Outcomes
Recurrence was defined as a ductal carcinoma in situ or invasive cancer of the ipsilateral breast or in any regional or distant sites [32] [33] [34] . A cancer was classified as a recurrence only if it occurred more than 120 days after definitive surgery [34] . Date and cause of death were obtained from Washington State death files. Second cancers in the contralateral breast were obtained from the SEER program registry and chart abstraction. They were considered censoring events in the analysis of recurrence.
Statistical analysis
Analysis of breast cancer recurrence
We compared users and nonusers of any antidepressant after diagnosis with respect to patient characteristics and features of their cancer using the Chi-square test for categorical variables and the t test for continuous variables. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and their 95 % confidence intervals (CI) to assess the association between antidepressant use and breast cancer recurrence risk while accounting for competing risks [39] . Time from diagnosis was the analytic timescale because we believed it would be a strong confounder [40] . Women entered the analysis (delayed entry) when they became at risk for recurrence, which was defined as 120 days after definitive surgery. They did not contribute any person-time before being at risk. Women were followed until the earliest of recurrence, second primary breast cancer diagnosis, death, disenrollment from Group Health, or end of study (chart abstraction date). Women were censored when they developed a second primary breast cancer, and thus, any recurrence occurring after the second primary was not included as a recurrence outcome. Covariates in all models were selected a priori and included age at diagnosis (18-49, 50-59, 60-69, 70-79, C80 years), year of diagnosis (1990-1994, 1995-1999, 2000-2004, 2005-2008) 2 ) in the year before diagnosis, smoking in the year before diagnosis (current, past, never/unknown), menopausal status in the year before diagnosis (peri-or premenopausal, postmenopausal based on self-report or, if missing, age \ 55 or age C 55) [42] , and Charlson comorbidity score (0, 1, C2). All variables were included as categorical variables. Endocrine treatment and Charlson comorbidity score were included as time-varying covariates. Persons with unknown ER/PR status and BMI were excluded from the main recurrence and mortality models. We conducted exploratory analyses with depression and CYP2D6-inhibiting medications that were ascertained in COMBO (statin, aspirin, beta-blocker, and insulin) as timevarying covariates in separate models.
In analyses of drug class and recurrence risk, we used two approaches to control for confounding by other antidepressants. We conducted one analysis in which we restricted (in a time-varying manner) to nonusers of any antidepressant and users of only the antidepressant class of interest. In this analysis, exposure was time varying in that women could switch from being a nonuser to a user of one class, but were censored when they used an antidepressant from another class. In the tables, these are referred to as ''restriction'' analyses. Separate models were conducted for each antidepressant of interest, and women were censored when they used another antidepressant. In the second approach, we included each class of antidepressants as a separate exposure variable in the model so that they were mutually adjusted for one another. In the tables, these are referred to as ''adjustment'' analyses.
We conducted an analysis limited to tamoxifen users (n = 1,902), 93 % of whom were ER positive or borderline, to address the question of whether antidepressants modify tamoxifen's effectiveness. For the analysis of concurrent tamoxifen use, women entered the analysis once they became at risk of recurrence and had used 60 days of tamoxifen (Supplemental Figure 1) . Women with aromatase inhibitor use before tamoxifen use were excluded. Women could be nonusers of antidepressants (i.e., tamoxifen only users), non-concurrent users of tamoxifen and antidepressants, or concurrent users of tamoxifen and antidepressants. Concurrent use of antidepressant and tamoxifen was time varying and occurred once a woman had 60 days of overlap of tamoxifen and antidepressant Cancer Causes Control (2016) 27:125-136 127 use. We conducted separate models for concurrent use of tamoxifen and any antidepressant as well as with each antidepressant drug and drug class. Due to small sample size, we adjusted only for diagnosis age, diagnosis year, and stage at diagnosis in these models. Women were censored at the earliest of the start of an aromatase inhibitor, second primary breast cancer, death, disenrollment, or end of study follow-up.
Analysis of breast cancer mortality
In a secondary analysis, we examined the risk of breast cancer-specific mortality in relation to antidepressant use, using multivariable Cox models with the same exposures of interest as in the main analysis. Once a person started using an antidepressant, she was classified as a user; however, new use after a recurrence diagnosis or second primary was not included, as recurrences and second primaries were likely to be strong time-varying confounders [43] . We followed women until the earliest of death from another cause, Group Health disenrollment, or end of study follow-up.
Proportional hazards assumptions
We evaluated proportional hazards assumptions by testing the interaction between the medication classes of interest and the logarithm of follow-up time. Separate tests were run for breast cancer recurrence and mortality outcomes.
The assumptions held for all exposure-outcome pairs except for miscellaneous antidepressants and breast cancer mortality and any antidepressant and breast cancer mortality. To further assess the non-proportional hazards for, we divided the follow-up time into two periods each containing half the breast cancer deaths (B4.24 years since diagnosis and [4.24 years). Separate HRs for exposures were estimated for each time period by including an interaction term between time period and the exposure in the multivariate Cox proportional hazards model. For both any antidepressant and miscellaneous antidepressants models, the HRs in the two time periods were not statistically significant and the confidence intervals overlapped. Therefore, we report the overall results for both miscellaneous antidepressants and any antidepressant.
Results
Among the 4,216 women who met study eligibility criteria, more than half (n = 2,302, 54.6 %) filled at least one prescription for an antidepressant sometime after their incident breast cancer diagnosis (but before recurrence or second primary). Antidepressant users were more often white, were more likely to smoke at baseline, have a mental health diagnosis and filled prescriptions for antidepressants in the year before diagnosis, have lower education levels, have more comorbidities, and have higher BMI than participants who did not use antidepressants after breast cancer diagnosis (Table 1) . Users and nonusers were generally similar with respect to risk factors for recurrence, such as stage and other features of initial cancer. However, compared with nonusers, antidepressant users were slightly more likely to receive mastectomy over breast-conserving surgery with radiation and to receive chemotherapy. The median duration of use after breast cancer diagnosis for all antidepressants was 23 months (Table 2) , and median time to first use was 7.4 months (not shown). SSRIs were the most commonly used class of antidepressants. Of all individual antidepressants, fluoxetine and trazodone were the two most frequently used agents. Overall, use of antidepressants after incident breast cancer diagnosis was not associated with risk of recurrence (adjusted HR: 1.16, 95 % CI 0.94, 1.44) compared with nonusers (Table 3) . HRs for both SSRIs and TCAs were near 1.0 and were not statistically significant. Miscellaneous antidepressants were associated with a nonsignificant increased risk, possibly driven by the most commonly used of these medications, trazodone (adjusted HR: 1.76; 95 % CI 1.06, 2.92). We observed an increased recurrence risk among women taking paroxetine only (adjusted HR: 1.66; 95 % CI 1.02, 2.71), but not fluoxetine only (adjusted HR: 0.92; 95 % CI 0.55, 1.53). Risk estimates were elevated for citalopram users, but were based on only three events in the user group.
The median time to tamoxifen initiation among nonconcurrent tamoxifen and antidepressant users was shorter than among tamoxifen only or concurrent tamoxifen and antidepressant users (2.6, 3.7, and 3.9 months, respectively). The total duration of tamoxifen use in these groups was similar (97, 94, and 98 months, respectively). In the analysis restricted to tamoxifen users, concurrent use of most antidepressants was not associated with recurrence risk (Table 4 ). There was some suggestion of a decreased risk associated with concurrent weak CYP2D6 inhibitor use (adjusted HR: 0.51; 95 % CI 0.16, 1.62) and increased risk with concurrent paroxetine use (adjusted HR: 1.49; 95 % CI 0.79, 2.83). However, these estimates were based on only 6 and 16 events in the concurrent user groups, respectively. There were even fewer events among nonconcurrent antidepressant users. For fluoxetine, recurrence risk was elevated with non-concurrent (adjusted HR: 2.21, CI: 1.04, 4.66) tamoxifen use, but not concurrent use.
Results from the sensitivity analysis requiring C180 days of overlap for concurrent use had little effect on most estimates. There was a change in the hazard ratio for nonconcurrent paroxetine and tamoxifen use (from 0.95 [95 % 
Discussion
Our study provides some reassurance that many commonly used antidepressant medications are not associated with an increased risk of breast cancer recurrence. Results from this large, population-based retrospective cohort study are generally consistent with other studies that have generally not observed an increased risk of breast cancer recurrence with antidepressant use [6] .
We hypothesized that paroxetine and fluoxetine would increase recurrence risk among tamoxifen users because these antidepressants inhibit the conversion of tamoxifen to its active form [5] [6] [7] . There was a suggestion of increased risk with concurrent paroxetine use among tamoxifen users. This finding is consistent with a prior study (odds ratio for recurrence: 2.4, 95 % CI 0.6-9.5) [22] , but not another (HR for disease free survival: 0.84; 95 % CI 0.34-2.05) [25] . Of note, all three studies (including ours) had wide confidence intervals.
Among tamoxifen users, we also observed that fluoxetine was associated with an increased risk of recurrence when taken separately from tamoxifen (i.e., non-concurrently) but not at the same time (i.e., concurrently). This is AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, SD standard deviation, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant a Column percents may not add to 100 % due to rounding surprising and inconsistent with the biological hypothesis, which would suggest that fluoxetine, a strong CYP2D6 inhibitor, would affect breast cancer recurrence risk by reducing tamoxifen's effectiveness if the two medications were used concurrently. In general, our findings for nonconcurrent antidepressant use among tamoxifen users should be cautiously interpreted due to small sample size. We saw an increased risk of recurrence with trazodone use. Trazodone may be a weak/moderate CYP2D6 inhibitor [30, 44] , but to our knowledge, other studies have not looked specifically at the risk of recurrence in relation to trazodone use. Given trazodone is commonly used for insomnia [45] , it is unclear whether our findings are due to chance or confounding by indication. The suggested increased risk of recurrence with citalopram should also be interpreted cautiously as it was based on only three events and is not consistent with findings from larger studies [22, 23, 31] . Similarly, the small number of deaths due to breast cancer in each drug exposure category limits our ability to draw conclusions.
Our study had relatively long follow-up and high-quality longitudinal, prospectively collected data on exposures, outcomes, and confounders with gold standard chart review for many of these variables. Variables were not subject to recall bias; however, exposure status may have been misclassified if women did not consume the prescriptions they filled or if they filled prescriptions that did not result in a claim. Another limitation was that we had a very small number of events when examining individual drugs, particularly for analyses of non-concurrent use among patients taking tamoxifen. This has been a common issue in other studies of specific antidepressant use and breast cancer recurrence [22, 23, 25, 26, 31] and motivates the need for pooled meta-analyses on specific drugs. We anticipated this SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, CI confidence interval a All estimates are from separate models accounting for competing risks. Adjusted for age at diagnosis (18-49, 50-59, 60-69, 70-79, 80? years), year of diagnosis (1990-1994, 1995-1999, 2000-2004, 2005-2008 , smoking in the year before diagnosis (current, past, never/ unknown), menopausal status in the year before diagnosis (peri-or premenopausal, postmenopausal), and Charlson score (0, 1, 2?). Total number of participants in adjusted model was 3,979 due to exclusion of women with unknown ER/PR status or BMI in the year before diagnosis b Unexposed groups for these analyses, i.e., nonusers of specific antidepressants, are not given in this table problem, but believed that these analyses were still important to conduct. Women will benefit from having information about the risk profiles of individual antidepressants to make decisions about which may be safer to use after breast cancer diagnosis. Last, COMBO uses data from a single health plan and includes an educated, primarily white population, and individuals with access to both medical care and prescription drug benefits. This may limit generalizability to some populations if the biological effect of antidepressants differs by patient characteristics.
Having access to the most important predictors of cancer recurrence (i.e., disease characteristics) helped reduce Confounding by indication is also a possibility in this study; even though all medications studied are used for depression, some have other indications (e.g., anxiety, pain, and sleep). We did not have information on the reason for antidepressant use and therefore could not adjust for it. It is also possible that antidepressants were used for symptoms of an undiagnosed recurrence. Under such circumstances, antidepressants could appear to increase the risk of recurrence due to reverse causality (i.e., protopathic bias). To protect against confounding by indication in the breast cancer mortality analysis (i.e., a woman started using antidepressants because she had a recurrence), we counted only exposure initiated before recurrence [43] . We did not have information on CYP2D6 genotype, which could be a limitation if it were associated with antidepressant use.
Conclusions
Our results provide important information on antidepressant use after breast cancer diagnosis including information on individual drugs, which-when combined systematically and quantitatively with results from other studiesmay be useful for patients and providers making decisions about whether to use these medications. SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, CI confidence interval a All estimates are from separate models. Adjusted for age at diagnosis (18- , smoking in the year before diagnosis (current, past, never/unknown), menopausal status in the year before diagnosis (peri-or premenopausal, postmenopausal), and Charlson score (0, 1, 2?). Total number of participants in adjusted model was 3,924 due to exclusion of women with unknown ER/PR status or BMI in the year before diagnosis b Unexposed groups for these analyses, i.e., nonusers of specific antidepressants, are not given in this 
